Drug
TPI-287 clinical trials
Also written TPI 287 and NBT 287.
- studies test it
- 17
- open now
- 0
- in phase 3
- 0
- first study started
- 2005
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 2005 | 2 |
| 2007 | 2 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 12
- Phase 2
- 10
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 11
Cortice Biosciences, Inc. (6) · M.D. Anderson Cancer Center (5) · Giselle Sholler (3) · University of California, San Francisco (2) · H. Lee Moffitt Cancer Center and Research Institute (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses TPI-287 is read from its arms, and is right about nine times in ten.
Testing it · 17
- TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or MedulloblastomaCompletedPhase 1Giselle ShollerNCT00867568Written as TPI 287
- Safety and Efficacy Study of TPI-287 in Neuroblastoma and MedulloblastomaTerminatedPhase 1/2Giselle ShollerNCT01483820Written as TPI 287
- Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed NeuroblastomaTerminatedPhase 1/2Giselle ShollerNCT01505608Written as TPI 287
- Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for GlioblastomaSuspendedPhase 1/2Cortice Biosciences, Inc.NCT01933815Written as TPI 287
- Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain MetastasesTerminatedPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT02187822Written as TPI 287
- Safety Study of TPI-287 to Treat CBS and PSPCompletedPhase 1University of California, San FranciscoNCT02133846Written as TPI 287 2 mg/m2
- A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's DiseaseCompletedPhase 1University of California, San FranciscoNCT01966666Written as TPI-287 2 mg/m2
- Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent GlioblastomaTerminatedPhase 1/2M.D. Anderson Cancer CenterNCT01582152Written as TPI287
- TPI 287 in Breast Cancer Metastatic to the BrainCompletedPhase 2M.D. Anderson Cancer CenterNCT01332630Written as TPI 287
- Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin TherapyTerminatedPhase 2Cortice Biosciences, Inc.NCT02047214Written as TPI 287
- A Phase I Study of TPI 287 - Temozolomide Combination in MelanomaTerminatedPhase 1M.D. Anderson Cancer CenterNCT01067066Written as TPI 287
- TPI 287 in Patients With Recurrent Glioblastoma MultiformeTerminatedPhase 2M.D. Anderson Cancer CenterNCT01113463Written as TPI 287
- A Phase II Trial of TPI 287 in Patients With Metastatic Prostate CancerTerminatedPhase 2Cortice Biosciences, Inc.NCT00479635Written as TPI 287
- A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic CancerTerminatedPhase 2Cortice Biosciences, Inc.NCT00553813Written as TPI 287
- Open-Label Study of TPI 287 for Patients With Metastatic MelanomaWithdrawnPhase 1/2M.D. Anderson Cancer CenterNCT01340729Written as TPI 287
- Study of TPI 287 in Patients With Advanced MalignanciesCompletedPhase 1Cortice Biosciences, Inc.NCT00113724Written as TPI 287 Injection
- Study of TPI 287 Administered Every 21 Days in Patients With Advanced MalignanciesCompletedPhase 1Cortice Biosciences, Inc.NCT00256191Written as TPI 287 Injection
Codes
What other systems call TPI-287 · ClinicalTrials.gg INT006223
- Wikidata Q27273546tpi-287One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| Wikidata | Q27273546 | tpi-287 | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.